A Single-Center, Prospective Cohort Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 80
Healthy Volunteers: f
View:
• Signed informed consent
• Aged 55-80 years old
• Diagnosis of RMS according to the 2017 Revised McDonald criteria
• Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label
Locations
United States
Massachusetts
Neurology Center of New England P.C.
RECRUITING
Foxborough
Contact Information
Primary
Salvatore Napoli, MD
ksciore@myneurodr.com
781-551-5812
Backup
Rachel ODonnell, BS
ResearchNCNE@myneurodr.com
781-551-5812
Time Frame
Start Date: 2024-08-13
Estimated Completion Date: 2027-09-30
Participants
Target number of participants: 20
Related Therapeutic Areas
Sponsors
Leads: Neurology Center of New England P.C.